Pfizer Rocky Mount Turns to SteraMist for Post-Tornado Decontamination
- TOMI has established a long-term relationship with Pfizer, showcasing the trust and loyalty of its clients. The utilization of SteraMist iHP Corporate Service since 2014 demonstrates the effectiveness and reliability of TOMI's decontamination technology. Pfizer's decision to engage TOMI for emergency decontamination highlights the crucial role TOMI plays in critical situations, emphasizing the company's importance in the industry.
- None.
FREDERICK, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that Pfizer Rocky Mount has engaged TOMI's iHP Corporate Service to conduct emergency decontamination within their facility, which suffered substantial damage due to a recent tornado.
Pfizer Rocky Mount has been a long-term, loyal client of TOMI, having commenced their utilization of SteraMist iHP Corporate Service in 2014. Since then, TOMI has been performing decontamination service twice a year during their facility's routine scheduled shutdowns and called on as necessary throughout the years.
Following the recent tornado's destructive impact, Pfizer sought assistance from TOMI for their decontamination needs. Given the urgency of resuming production after the facility was devastated by the natural disaster, the speed of SteraMist iHP technology is paramount. Pfizer first contracted TOMI due to their superior material compatibility and four times faster speed, replacing vaporized hydrogen peroxide (VHP) and disrupting the industry with a new ground-breaking technology. SteraMist has since replaced VHP in many life science facilities across the world. TOMI has been granted acceptance as a global supplier from Pfizer and continues to expand its SteraMist iHP Corporate Services, Custom Engineered Systems, and fleet of SteraMist handheld surface and full room fogging equipment across Pfizer facilities.
"Pfizer has utilized SteraMist decontamination technology extensively over the years to uphold sterile manufacturing facilities, going above and beyond standard pharmaceutical critical contamination control strategy," stated Jim Reynolds, an established TOMI representative. He further noted, "Across the globe, SteraMist consistently supersedes VHP, providing unmatched speed, high log efficacy, and superior material compatibility in one decontamination technology. Pfizer remains a steadfast partner, and we are proud to continue our efforts in enhancing their decontamination processes."
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit https://steramist.com/ or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to SteraMist’s opportunities in the new partnership. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Important factors that could affect our performance and cause results to differ materially from management’s expectations are described in the section entitled “Risk Factors,” in our Annual Report on Form 10-K and other SEC filings. These factors include: our history of losses that may prevent us from achieving profitability in the future; our lack of long-term customer contracts and our inability to rely on our sales history or backlog as an indicator of our future sales; that we are subject to a variety or risks associated with doing business internationally; our success in business depends on our ability to adequately protect our intellectual property; and that our stock price is volatile and there is a limited market for our shares. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
FAQ
What does TOMI Environmental Solutions, Inc. do?
Why did Pfizer Rocky Mount engage TOMI's iHP Corporate Service?
What technology does TOMI use for decontamination?
